FY2025 · ended Dec 28, 2025 · Revenue $94.19B, +6.0% YoY · Filed Feb 11, 2026
Johnson & Johnson (JNJ) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 28, 2025, it reported revenue of $94.2 billion and net income of $26.8 billion. Free cash flow was $19.7 billion. As of Sep 27, 2026 it held $17.2 billion in cash and investments and $44.7 billion in total debt.
Revenue (TTM)
$99.33B
+7.8% vs year-ago TTM
Net income (TTM)
$16.09B
-35.9% vs year-ago TTM
Operating cash flow (TTM)
$26.16B
+8.1% vs year-ago TTM
Free cash flow (TTM)
$20.59B
+5.1% vs year-ago TTM
EPS (TTM)
$6.58
-36.4% vs year-ago TTM
Dividend per share (TTM)
$5.28
+3.9% vs year-ago TTM
Shares outstanding
2.41B
+0.1% vs prior year
Net cash
$-27.42B
as of Sep 27, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JNJ (NYSE)
- Fiscal year ends
- January 3
- Incorporated in
- NJ
- Headquarters
- New Brunswick, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 200406
- Former names
- JOHNSON & JOHNSON ET AL (until Jan 23, 1996)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 28, 2025 |
FY 2024 Dec 29, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Jan 1, 2023 |
FY 2021 Jan 2, 2022 |
|---|---|---|---|---|---|
| Revenue | $94.2B | $88.8B | $85.2B | $80.0B | $78.7B |
| Net income | $26.8B | $14.1B | $35.2B | $17.9B | $20.9B |
| Diluted EPS | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 |
| Operating cash flow | $24.5B | $24.3B | $22.8B | $21.2B | $23.4B |
| Free cash flow | $19.7B | $19.8B | $18.2B | $17.2B | $19.8B |
| Total assets | $199.2B | $180.1B | $167.6B | $187.4B | $182.0B |
| Total liabilities | $117.7B | $108.6B | $98.8B | $110.6B | $108.0B |
| Stockholders' equity | $81.5B | $71.5B | $68.8B | $76.8B | $74.0B |
| Cash and investments | $20.1B | $24.5B | $22.9B | $22.3B | $31.6B |
| Total debt | $51.3B | $39.6B | $31.9B | $42.5B | $36.9B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 21, 2026 | Sep 27, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 13, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 29, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 28, 2026 | Jul 27, 2026 |
| 10-Q | Quarterly report | Jul 23, 2026 | Jun 28, 2026 |
All 1000 Johnson & Johnson SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.